The US Food and Drug Administration (FDA) on Wednesday released final guidance for sponsors on when a standard release test and criteria may be used in lieu of extensive method development and ...
System addresses the pharmaceutical industry’s need for compliant, semi-automated testing of nanoparticle drug formulations. SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) ...
When you take a time-release drug, you count on it doing what the package says: release the drug slowly into your bloodstream to provide benefits over the specified period of time. When the drug ...
Low-dose dissolution frequently demands reduced media volumes to keep early time-point concentrations above LOQ, and regulators may expect evaluation of higher-sensitivity analytics before lowering ...
High-speed industrial particle size reduction is essential for controlling particle distribution, enhancing dissolution rates ...
The British Pharmacopoeia on Monday released its response to its consultation on dissolution testing and announced its plans to update its approach within its product monographs. The British ...
Pharmaceuticals are developed, designed, and commonly manufactured in laboratory settings. Laboratory testing is an essential need in almost every stage of pharmaceutical production and R&D, from the ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of the NanoDis System for nanoparticle dissolution testing. Combining Agilent instrumentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results